Article

MÉTODO DÁDER DE SEGUIMIENTO FARMACOTERAPÉUTICO Y FARMACOVIGILANCIA EN INSTITUCIONES DE SALUD DE COLOMBIA

Vitae (Impact Factor: 0.15). 01/2005; 12(1):29-38.

ABSTRACT The Pharmacovigilance pretends to satisfy the need of information related to the results of pharmacotherapy, at the same time, it turns into a tool for preventing risks and decreasing costs caused by the undesired effects of the pharmacotherapy. In Colombia, the DADER method for drug therapy follow-up has shown that it is possible to accomplish with the goals of pharmacovigilance. However, more support is required about the utility and benefits achieved with its implementation in a larger number of health institutions. In this sense, a retrospective descriptive study of the results of drug therapy follow-up by the Dader method, it is carried out both at ambulatory health institutions and at hospital health institutions, by students of the Pharmacy program, at the University of Antioquia, who participated in the courses of clinical pharmacy practices or professional practices, from august 2003 to november 2004. During this period: 4.556 patients were followed and 660 problems related to drugs and 3.581 problems related to the use of drugs were detected. These results confirm the usefulness and additional benefits of the drug therapy follow-up of patients by the DADER method, about the fulfillment of the necessity to arrange and to expand pharmacovigilance programs in the Colombia Health System.

0 Bookmarks
 · 
97 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The pharmacotherapy follow-up is a process by which the pharmacist detects, prevents and solves drug therapy problems (DTP). The Dader method becomes visible like a fundamental instrument to achieve this task. In Colombia, the drug therapy follow-up programs are limited. Therefore, in the context of Colombia, the Dader method for drug therapy follow-up of patients was put into practice and the importance of the concept and classification of drug therapy use problems (DTUP) were demonstrated. In this descriptive study, by 5 months we enrolled, assisted, and followed-up 498 patients. In this period, 92 DTP were identified (0.2 DTP per patient) and 508 DTUP (1.1 DTUP per patient). In the group of DTP, 42 were of necessity, 22 of effectiveness and 28 of safety; whereas out of the total amount of DTUP, 340 were related to use, 155 to prescription, 7 to dispensation and 6 were related to availability. The 90.2% of the DTP and 87.2% of the DTUP detected was solved. In Colombia this results evidence that the DADER method is effective and efficient to carry out drug therapy follow-up; and it has to be link to target to detect and solve DTUP.
    Pharmacy Practice. 01/2003; 1(3):99-104.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pharmaceutical care started in the nineties in the United States and has rapidly extended in many other countries. Although there are different trends, such as clinical pharmacy services, cognitive services, medication management, medication review, they all share the same philosophy and objectives, namely "the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient's quality of life". To attain these objectives, a pharmaceutical care process has to be followed point-by-point in order to detect possible medication-related problems. Furthermore, pharmacists have to work together with patients, and ultimately with physicians to establish a care plan. This methodology requires basic skills of documentation and communication and therefore, it is important to establish implementation programs aimed at community-, hospital-, and consultant pharmacists, and to consider PC as a basic element of University teaching programs and postgraduate studies. Moreover, there are still barriers that hinder the provision of this service and have to be overcome. In this article, we have revised the implementation process and the existing projects in many countries and we conclude that despite the enormous amount of work, there is still much to be done from sides of Administration and pharmacists themselves.
    Current Pharmaceutical Design 02/2004; 10(31):3969-85. · 3.31 Impact Factor

Full-text

View
3 Downloads
Available from